Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shanghai Haoyuan Chemexpress Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.56%.
Shanghai Haoyuan Chemexpress Co (SHSE:688131) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Shanghai Haoyuan Chemexpress Co ROCE % Related Terms
Shanghai Haoyuan Chemexpress Co ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haoyuan Chemexpress Co (SHSE:688131) has a ROCE % of 7.56% as of Mar. 2026.
Is Shanghai Haoyuan Chemexpress Co's ROCE % too high?
Shanghai Haoyuan Chemexpress Co's current ROCE % is 7.56%. The Drug Manufacturers industry median ROCE % is 7.04. Shanghai Haoyuan Chemexpress Co's value of 7.56% is 7.4% above this industry median. Overall, Shanghai Haoyuan Chemexpress Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haoyuan Chemexpress Co's ROCE % compare to ZTS and UTHR?
Shanghai Haoyuan Chemexpress Co's ROCE % of 7.56% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. Shanghai Haoyuan Chemexpress Co's value of 7.56% is 7.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haoyuan Chemexpress Co's current ROCE % of 7.56% is 7.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haoyuan Chemexpress Co's current ROCE % is 7.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haoyuan Chemexpress Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co (SHSE:688131) is currently considered Fairly Valued. The stock's GF Value™ is ¥65.89, compared to a current price of ¥70.55 — trading 7.1% above its estimated fair value. The current ROCE % is 7.56% and 7.4% above the Drug Manufacturers industry median of 7.04. Shanghai Haoyuan Chemexpress Co's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Shanghai Haoyuan Chemexpress Co (SHSE:688131), the current ROCE % is 7.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haoyuan Chemexpress Co (SHSE:688131) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co stock appears to be overvalued.
The current stock price of ¥70.55 is trading 7.1% above its estimated GF Value™ of ¥65.89.
GuruFocus considers Shanghai Haoyuan Chemexpress Co to be Fairly Valued.
Key valuation signals for SHSE:688131:
ROCE %: 7.56%
GF Value™: ¥65.89 vs. price of ¥70.55 (7.1% above fair value)
Industry Position: 7.4% above the Drug Manufacturers median
No single metric tells the full story. See the SHSE:688131 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haoyuan Chemexpress Co Business Description
Shanghai Haoyuan Chemexpress Co Ltd focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. The company's comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. It is a one-stop service platform to support client's projects from early drug discovery, process development to commercialization. The company is committed to delivering high-quality products and CMC services to clients across the entire life cycle of drug development.
92GF Score
Get the complete analysis for SHSE:688131
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688131 has been successfully added to your 
